Medtronic plc Q1 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Health Care Equipment and Supplies | Market Cap: ₹97.0K Cr
- Renal denervation (RDN) shows strong consumer demand with visits jumping from 50,000 in Q2 to 2.5 million in Q3; over 200 new accounts opened and 150 physicians trained. - Fiscal ’26 organic revenue growth guidance reiterated at approximately 5.5%, with Q4 expected at around 6% growth.
From Medtronic plc's Q1 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹75.57
Market Cap
₹97.0K Cr
P/E Ratio
21.7
Revenue Rank
Margin Rank
How does Medtronic plc rank in Health Care Equipment and Supplies?
Compare Medtronic plc against every Health Care Equipment and Supplies company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Renal denervation (RDN) shows strong consumer demand with visits jumping from 50,000 in Q2 to 2.5 million in Q3; over 200 new accounts opened and 150 physicians trained.
- →CAS (Catheter Ablation System) revenue is expected to double, reaching $2 billion trailing by first half FY ’27 with continued high teens to strong double-digit market growth.
- →New product launches like Sphere-9 in Japan and Sphere-360 in Europe (with US trial ongoing) fuel growth in CAS.
- →Altaviva (tibial neurostimulation) and Symplicity (hypertension treatment) are early-stage but growing rapidly with direct-to-consumer marketing amplifying traction.
- →Hugo robotic surgical system just launched in the US with initial successful installations; expected to expand indications and drive growth.
- →Other segments like Neurovascular, CST, and CRM are accelerating, contributing to overall revenue growth.
- →Fiscal ’27 guidance anticipates accelerating revenue growth with high single-digit EPS growth, supported by these innovation drivers.
📈 Profitability & Margins
Rank 3- →Fiscal ’26 organic revenue growth guidance reiterated at approximately 5.5%, with Q4 expected at around 6% growth.
- →Adjusted operating profit expected to grow approximately 5% or 7% excluding tariffs in fiscal ’26, with operating margin roughly flat excluding tariffs.
- →Gross margin anticipated to increase slightly ex tariffs in fiscal ’26, despite tariff impacts of ~$185 million.
- →Fiscal ’27 EPS growth guidance is high single digits, driven by accelerated growth, improved gross margins (mix shift toward more catheters, separation of Diabetes business), and leverage in G&A.
- →Continued investments in R&D, sales, marketing, and M&A expected but net leverage from SG&A and functional areas will support margin expansion.
- →Some temporary EPS dilution (around $0.01-$0.02) from Diabetes separation and M&A dilution ($0.04-$0.05) expected in fiscal ’27, but offset over time.
- →Strong growth drivers include CAS, renal denervation (RDN), Altaviva, Hugo robot, Stealth AXiS, and Neurovascular pipeline.
🏗️ Capital Expenditure Plans
Yes- →Medtronic is increasing R&D investment, particularly in high-growth areas like renal denervation (RDN), CAS, and robotics (Stealth AXiS and Hugo).
- →Direct-to-consumer marketing investments are being made to build referral pathways and brand awareness, e.g., for Symplicity in hypertension management.
- →The company is hiring extensively, including mappers and roles focused on market development, health economics, coding, and billing.
- →Medtronic is shifting to a more offensive capital allocation stance, combining organic investments with strategic M&A.
- →M&A focus remains on tuck-in deals and venture investments in close adjacency to existing business areas, with several opportunities prioritized.
- →Investments in robotics (Stealth AXiS) and other innovative technologies are viewed as key generational growth drivers.
- →Continuous investments fuel growth initiatives and support acceleration in revenue and earnings for FY ’27 and beyond.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
Yes- →Hugo Surgical System: Orders and installations are ramping up, with initial U.S. cases completed at Cleveland Clinic and more scheduled, indicating a growing order book.
- →Renal Denervation (Symplicity): Over 200 new account openings this quarter, reflecting strong market development and growing procedure volumes; physician participation increasing with 150+ physicians in the referral network.
- →CAS (Cardiac Ablation Systems): Trailing 12-month revenue goal target of $2 billion expected by FY '27 first half, supported by catheter portfolio strength and new product launches (Sphere-9 and Sphere-360) with ongoing trial and market expansion; strong installed base growth.
- →Stealth AXiS Robotics: Early-stage adoption with positive clinical and surgeon feedback; expected to increase orders as it integrates into existing workflows, enhancing competitive position.
- →CathWorks & Anteris: Focused on tuck-in M&A supporting product pipeline expansion and potential orders in adjacencies, implying strategic capital deployment toward growing order backlog.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Equipment and Supplies this season
- The Cooper Companies, Inc. (Q1 FY26)
The Cooper Companies, Inc. Q1 FY26 quarterly results analysis. Fiscal 2026 revenue guidance is $4.3 billion to $4.35 billion, reflecting organic growth of 4.5%
Frequently Asked Questions
What were Medtronic plc Q1 FY26 results?
- Renal denervation (RDN) shows strong consumer demand with visits jumping from 50,000 in Q2 to 2.5 million in Q3; over 200 new accounts opened and 150 physicians trained. - Fiscal ’26 organic revenue growth guidance reiterated at approximately 5.5%, with Q4 expected at around 6% growth.
What is Medtronic plc share price analysis?
Medtronic plc currently shows a below-average growth signal. The stock trades at a P/E of 21.7 with a market cap of $97,023. Investors should review the full earnings analysis for detailed insights.
Is Medtronic plc planning capital expenditure?
- Medtronic is increasing R&D investment, particularly in high-growth areas like renal denervation (RDN), CAS, and robotics (Stealth AXiS and Hugo).
Keep Medtronic plc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.